Argireline vs Botox: can a topical peptide really relax wrinkles?

The idea: copy the target, not the toxin

Botulinum toxin works by cutting SNAP-25, one of the proteins nerve endings need to release acetylcholine. Without that release, the injected muscle relaxes, and the lines it creates in the skin above it soften. Botox Cosmetic's label describes it as an acetylcholine release inhibitor and a neuromuscular blocking agent ¹.

Argireline Medium, sold in ingredient lists as acetyl hexapeptide-8 or acetyl hexapeptide-3, takes a different approach. Its sequence, Ac-EEMQRR-NH2, came from a rational design programme aimed at mimicking a short stretch of SNAP-25, so that it would compete with the real protein and loosen the assembly that releases neurotransmitter. In laboratory tests it did inhibit neurotransmitter release in a way resembling botulinum toxin A, but with much lower efficacy ². That is the origin of the "Botox in a jar" label: a peptide that acts on the same machinery, applied to the skin rather than injected into the muscle.

The idea is reasonable as far as it goes. The question is not whether argireline can interfere with nerve signalling in a dish; it can. The question is whether enough of it reaches the place where that signalling happens.

The penetration problem

The muscles of facial expression lie beneath the skin, under the epidermis and the dermis. A topical ingredient that relaxes them has to cross the outer barrier of the skin, the stratum corneum, and then travel a long way further. Argireline is a poor candidate for that journey: a 2025 review of its skin permeability notes that it is water-loving and relatively large, so it crosses the oily stratum corneum poorly, and concludes that its ability to reach neuromuscular junctions remains uncertain ³.

The most direct measurement comes from a laboratory at the US FDA. Researchers applied an oil-in-water emulsion containing 10% argireline to human cadaver skin and guinea-pig skin in diffusion cells for 24 hours, then measured where it went. Most of it was washed off the surface. Of what stayed, 0.22% of the applied dose was in the stratum corneum of human skin, the outermost dead layer, and 0.01% had reached the epidermis. None was detected in the dermis or in the fluid beneath the skin ⁴. A second laboratory study found that the type of cream matters: a water-in-oil-in-water emulsion delivered significantly more argireline into pig skin than simpler emulsions ⁵. Better formulation can push more peptide into the outer layers; nothing in these studies shows it reaching muscle.

This does not mean argireline does nothing. Effects on the skin itself, on hydration or texture, would not require it to reach muscle. It does mean that the specific claim, relaxing the muscles that cause expression lines as Botox does, is the claim with the least support.

What the argireline studies measured

The human evidence is small. The design paper reported that a 10% emulsion reduced wrinkle depth by up to 30% over 30 days in healthy women ²; that was the developer's own study. A randomised trial in 60 Chinese adults, allocated three to one to argireline or placebo twice daily for four weeks, found that assessors rated 48.9% of the argireline group improved against none on placebo, and that skin roughness on replicas fell only with argireline ⁶. In a 24-volunteer randomised study comparing argireline, a second peptide, both together and neither over 60 days, the argireline groups showed improvements in skin microtopography and water loss through the skin ⁷. A small Indonesian trial around the eyes found that some participants improved on acetyl hexapeptide-3 cream or on palmitoyl pentapeptide-4 cream ⁸.

These studies share limits. They are short, small, often funded or designed close to the ingredient's makers, and their outcomes are instrument readings of skin texture or assessor ratings rather than the standardised frown-line scales used for Botox. None compared argireline with an injection.

One study tested the toxin and the peptide together. In 24 people receiving botulinum toxin injections for blepharospasm, an eyelid-spasm condition, adding daily topical argireline trended toward longer symptom control, 3.7 months against 3.0 on placebo, without significant side effects ⁹. As a pilot it is a curiosity, not evidence that a cream can stand in for the injection.

What the Botox Cosmetic label shows

Botox Cosmetic is approved for the temporary improvement of moderate to severe frown lines between the eyebrows, crow's feet, forehead lines and neck bands in adults ¹. Its frown-line approval rests on two randomised, double-blind, placebo-controlled trials of identical design: 405 adults received a single treatment of 20 units, injected into five sites in the muscles between the brows, and 132 received placebo. At day 30, investigators rated 80% of the treated group as having no or mild frown lines at maximum frown, against 3% on placebo; 89% of treated participants rated their own lines at least moderately improved, against 7% ¹. The effect faded over months: by day 120, 25% were still rated responders by investigators ¹. The label gives the duration of effect for frown lines as about three to four months ¹.

The difference in kind is clear in the numbers. The injection delivers the active substance directly into the muscle and produces a large, measurable change in the specific lines it treats, within a week. The cream delivers almost none to the muscle and produces small changes in skin texture over weeks.

Safety: different products, different limits

Botox Cosmetic carries a boxed warning: effects of botulinum toxin products can spread from the injection site and cause symptoms such as generalised weakness, double vision, drooping eyelids and difficulty swallowing or breathing ¹. Its label also warns that botulinum toxin products are not interchangeable, among other precautions ¹. These are reasons it is given by trained clinicians, at labelled doses.

Argireline's main limit is regulatory and dose-related. The US Cosmetic Ingredient Review expert panel concluded in 2025 that acetyl hexapeptide-8 amide is safe in cosmetics at concentrations up to 0.005%, and that the data are insufficient to judge it safe at higher concentrations ¹⁰. That is notable given that the design study and the laboratory penetration test used 10% ^{2 4}. And injecting it, which some people do with products sold online, removes the one thing that keeps it gentle: the skin barrier. A 45-year-old woman developed mycobacterial abscesses in her forehead and temples a week after argireline injections, which took five months of antibiotics to clear ¹¹.

The bottom line (as of October 3, 2026)

Argireline is a cosmetic ingredient, not a drug: it is not approved for any medical use, and in the US it is regulated as a cosmetic ingredient, with the expert panel's concentration limit ¹⁰. It may modestly smooth skin texture over weeks, and the best evidence for that is a handful of small trials. The comparison with Botox is a marketing comparison: the two act on related machinery, but only the injection reliably gets there. Anyone choosing between them is really choosing between a skincare product with small effects and a prescription procedure with large, temporary ones and real risks; that second choice belongs with a clinician. Our guide to copper peptides for skin covers another peptide family sold for ageing skin, and the Matrixyl entry covers the collagen-signalling peptide often sold beside argireline.

Frequently asked questions

Does argireline work like Botox?

Only in theory. It was designed to interfere with the same nerve-signalling machinery and does so weakly in the laboratory, but in human skin tests almost none of it penetrated past the outer layer and none reached the dermis.

Does argireline reduce wrinkles?

Modestly, in small studies. A 60-adult randomised trial found 48.9% rated improved after four weeks against none on placebo, and other small studies found smoother skin texture.

How well does Botox work for frown lines?

In its label trials, 80% of people given 20 units had no or mild frown lines at day 30 against 3% on placebo, with the effect lasting about three to four months.

Is it safe to inject argireline?

No. It is a cosmetic ingredient, not an injectable drug, and a published case describes mycobacterial abscesses after argireline injections that took five months of antibiotics to clear.

Related on Grey Peptides

• Argireline
• Matrixyl
• Copper peptides for skin

Sources

1. Allergan (AbbVie). BOTOX Cosmetic (onabotulinumtoxinA) US prescribing information: sections 1, 2, 5 and 14 and boxed warning (DailyMed set 485d9b71-6881-42c5-a620-a4360c7192ab, effective October 18, 2024); read October 3, 2026.
2. Blanes-Mira, C., et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci, 24(5), 303-10. PMID: 18498523
3. Zdrada-Nowak, J., et al. (2025). Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci, 26(12). PMID: 40565185
4. Kraeling, M. E., et al. (2015). In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol, 34(1), 46-52. PMID: 24754410
5. Hoppel, M., et al. (2015). Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci, 68, 27-35. PMID: 25497319
6. Wang, Y., et al. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol, 14(2), 147-53. PMID: 23417317
7. Raikou, V., et al. (2017). The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol, 16(2), 271-278. PMID: 28150423
8. Aruan, R. R., et al. (2023). Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol, 16(2), 37-43. PMID: 36909866
9. Lungu, C., et al. (2013). Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol, 20(3), 515-518. PMID: 23146065
10. Johnson, W., Jr., et al. (2025). Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol, 44(2_suppl), 54S-63S. PMID: 40673537
11. Chen, C. F., et al. (2021). Mycobacterium abscessus infection after facial injection of argireline: A case report. World J Clin Cases, 9(8), 1996-2000. PMID: 33748252

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.